NasdaqGS:INCYBiotechs
A Look At Incyte (INCY) Valuation As New AI Drug Discovery Partnerships Gain Traction
Incyte (INCY) has moved to deepen its use of artificial intelligence in drug discovery, broadening collaborations with Genesis Molecular AI and Edison Scientific to plug advanced platforms directly into its research and development workflows.
See our latest analysis for Incyte.
Despite the recent AI collaboration headlines, the stock’s 30 day share price return of 2.65% contrasts with a decline of 3.65% over 90 days, while the 1 year total shareholder return of 51.23% points to stronger...